Dermira (NASDAQ:DERM) Stock Rating Upgraded by BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Dermira (NASDAQ:DERM) from a strong sell rating to a sell rating in a report released on Thursday, BidAskClub reports.

Several other research analysts also recently commented on DERM. Zacks Investment Research raised Dermira from a hold rating to a buy rating and set a $8.25 price objective for the company in a research note on Wednesday, February 13th. HC Wainwright started coverage on Dermira in a research note on Thursday, February 14th. They issued a buy rating and a $13.00 price objective for the company. Svb Leerink started coverage on Dermira in a research note on Friday, February 22nd. They issued an outperform rating and a $20.00 price objective for the company. Leerink Swann started coverage on Dermira in a research note on Friday, February 22nd. They issued an outperform rating for the company. Finally, ValuEngine raised Dermira from a sell rating to a hold rating in a research note on Tuesday, March 5th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $17.97.

NASDAQ DERM traded down $0.10 during mid-day trading on Thursday, hitting $9.87. The stock had a trading volume of 200 shares, compared to its average volume of 616,946. Dermira has a twelve month low of $6.00 and a twelve month high of $15.48. The company has a debt-to-equity ratio of 4.36, a quick ratio of 6.92 and a current ratio of 7.13. The company has a market cap of $523.26 million, a P/E ratio of -1.89 and a beta of 1.40.

Dermira (NASDAQ:DERM) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($1.49) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by ($0.39). Dermira had a negative net margin of 510.47% and a negative return on equity of 391.86%. The firm had revenue of $2.45 million during the quarter, compared to analyst estimates of $2.63 million. As a group, sell-side analysts predict that Dermira will post -5.2 EPS for the current fiscal year.

In other Dermira news, insider Eugene A. Bauer sold 35,000 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $15.00, for a total value of $525,000.00. Following the completion of the sale, the insider now directly owns 43,900 shares of the company’s stock, valued at approximately $658,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 14.80% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. GYL Financial Synergies LLC purchased a new stake in shares of Dermira in the first quarter valued at $288,000. Jane Street Group LLC lifted its position in shares of Dermira by 200.0% in the first quarter. Jane Street Group LLC now owns 39,493 shares of the biopharmaceutical company’s stock valued at $535,000 after acquiring an additional 26,328 shares in the last quarter. HighTower Advisors LLC lifted its position in shares of Dermira by 32.0% in the first quarter. HighTower Advisors LLC now owns 17,244 shares of the biopharmaceutical company’s stock valued at $235,000 after acquiring an additional 4,181 shares in the last quarter. Opaleye Management Inc. lifted its position in shares of Dermira by 433.3% in the first quarter. Opaleye Management Inc. now owns 400,000 shares of the biopharmaceutical company’s stock valued at $5,420,000 after acquiring an additional 325,000 shares in the last quarter. Finally, Macquarie Group Ltd. purchased a new stake in shares of Dermira in the first quarter valued at $2,033,000. 93.92% of the stock is owned by institutional investors and hedge funds.

About Dermira

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

Further Reading: What is the outlook for the FAANG stocks?

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

$1.50 Earnings Per Share Expected for Crown Holdings, Inc.  This Quarter
$1.50 Earnings Per Share Expected for Crown Holdings, Inc. This Quarter
T-Mobile Us Inc  Receives Consensus Recommendation of “Buy” from Brokerages
T-Mobile Us Inc Receives Consensus Recommendation of “Buy” from Brokerages
Gol Linhas Aereas Inteligentes SA  to Issue … Dividend of $0.00 on  June 28th
Gol Linhas Aereas Inteligentes SA to Issue … Dividend of $0.00 on June 28th
Enanta Pharmaceuticals Inc  Receives Average Rating of “Buy” from Brokerages
Enanta Pharmaceuticals Inc Receives Average Rating of “Buy” from Brokerages
China Unicom  Limited  Receives Average Recommendation of “Buy” from Brokerages
China Unicom Limited Receives Average Recommendation of “Buy” from Brokerages
$0.93 EPS Expected for CGI Inc  This Quarter
$0.93 EPS Expected for CGI Inc This Quarter


© 2006-2019 Ticker Report